Stay tuned and follow the latest
developments and news in Molecular Oncology.
Following the presentation of the ALASCCA trial at ASCO GI 2025, aspirin has emerged as a promising adjuvant therapy in patients with stage II–III colorectal cancer (CRC) harboring PI3K pathway alterations […]
Read More
We are pleased to share the latest publication featuring Prime DX in the International Journal of Molecular Sciences “Comprehensive Evaluation of a 1021-Gene Panel in FFPE and Liquid Biopsy for Analytical and Clinical Use” […]
Read More
ASCO 2025 Genekor’s Online Publications Genekor is excited to invite you to go through our 7 online publications at this year’s ASCO meeting in May 30 – June 3, 2025, Chicago, Illinois. […]
Read More
The scientific team of GeneKor had a strong presence at the 31st Hellenic Congress of Clinical Oncology, held in Athens from April 9–12, 2025. Our team participated with 10 scientific […]
Read More
With great joy and pride, we announce that Genekor Medical S.A. has officially received accreditation from the College of American Pathologists (CAP), one of the world’s leading organisations for the […]
Read More
Driven by innovation and committed to improving cancer patient care, two powerful companies from Greece and North Macedonia are joining forces. The rapidly growing Genekor Medical S.A., a leading Greek […]
Read More
We are proud to announce that Genekor Medical S.A. was honored with the Business Partner of the Year 2024 award at the recent Exact Sciences annual event in Rome. This […]
Read More
#DressinBlueDay Wearing blue this month has a special meaning for us at GeneKor. Blue is the color of support for those affected by colorectal cancer, one of the most common […]
Read More
The innovative prime DX® technology is compatible with both FFPET and PLASMA, offering a comprehensive approach to personalized cancer treatment. With 1,021 genes, including over 30 related to homologous recombination […]
Read More